Harmonising patient-access programmes:the Dutch DRUG Access Protocol platform

Authors :: Laurien J Zeverijn
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
Anke A M G Pisters van Roy
Lonneke Timmers
T H Ly Tran
Jolanda E de Boer
Gijsbrecht F de Wit
Birgit S Geurts
Hans Gelderblom
Henk M W Verheul
Nicole Blijlevens
A N Machteld Wymenga
Ferry A L M Eskens
Egbert F Smit
Haiko J Bloemendal
Emile E Voest
Medical Oncology
Internal medicine
AII - Cancer immunology
CCA - Cancer Treatment and quality of life
Source :: Zeverijn, L J, van Waalwijk van Doorn-Khosrovani, S B, van Roy, A A M G P, Timmers, L, Ly Tran, T H, de Boer, J E, de Wit, G F, Geurts, B S, Gelderblom, H, Verheul, H M W, Blijlevens, N, Wymenga, A N M, Eskens, F A L M, Smit, E F, Bloemendal, H J & Voest, E E 2022, ' Harmonising patient-access programmes : the Dutch DRUG Access Protocol platform ', The Lancet Oncology, vol. 23, no. 2, pp. 198-201 . https://doi.org/10.1016/S1470-2045(21)00707-5, The Lancet Oncology, 23(2), 198-201. Lancet Publishing Group, Lancet Oncology, 23, 198-201, Lancet Oncology, 23, 2, pp. 198-201
Publication Year :: 2022
Abstract: Item does not contain fulltext

Subjects :: Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]
Oncology
Urological cancers Radboud Institute for Health Sciences [Radboudumc 15]
Humans
Antineoplastic Agents
Health Services Accessibility
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Netherlands

Language :: English
ISSN :: 14702045
Database :: OpenAIRE
Journal :: Zeverijn, L J, van Waalwijk van Doorn-Khosrovani, S B, van Roy, A A M G P, Timmers, L, Ly Tran, T H, de Boer, J E, de Wit, G F, Geurts, B S, Gelderblom, H, Verheul, H M W, Blijlevens, N, Wymenga, A N M, Eskens, F A L M, Smit, E F, Bloemendal, H J & Voest, E E 2022, ' Harmonising patient-access programmes : the Dutch DRUG Access Protocol platform ', The Lancet Oncology, vol. 23, no. 2, pp. 198-201 . https://doi.org/10.1016/S1470-2045(21)00707-5, The Lancet Oncology, 23(2), 198-201. Lancet Publishing Group, Lancet Oncology, 23, 198-201, Lancet Oncology, 23, 2, pp. 198-201
Accession number :: edsair.doi.dedup.....e4e79f0dca3475d812d212a606ef4951
Full Text :: https://doi.org/10.1016/S1470-2045(21)00707-5